Medical Developments International Limited · ASX:MVP
Medical Developments International — FY2025 Earnings Presentation
21 slides from Medical Developments International's earnings presentation, Aug 21, 2025
Slide 1: FY25 Full Year Results
ASX:MVP FY25 FULL YEAR RESULTS 21 August 2025 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation contains summary information about Medical Developments International Limited (ACN 108340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in summary form only and
Slide 3: Important notice and disclaimer
Important notice and disclaimer Factors that could cause actual results to differ materially include: • the success of research and development activities (including clinical trials); • decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label
Slide 4: Key messages
Key messages Step-change in financials; accelerating volume growth is now the key priority • Group revenue of $39.1m (+18%) with improved results in Pain Management and Respiratory FY25 results • Margin improvements of ~$4m from enhanced pricing Margins, earnings • Significant operating cost reducti
Slide 5: FY25 Full Year Results
FY25 Full Year Results Revenue Pain Management revenue Respiratory revenue $39.1m $26.2m $12.9m +18% +23% +9% Underlying EBIT Reported NPAT Free cashflow $0.05m loss $0.1m profit $1.1m outflow (pcp $11.6m1 loss) (pcp $41.0m loss) +$12.9m 5 1. Underlying EBIT in the prior period excludes $21.5 millio
Slide 6: Strategic priorities
Strategic priorities Target milestones for FY25 achieved FY25 strategic priorities Progress Improve margins through pricing and • Margin improvements of $4 million delivered through higher pricing operational efficiency • Cost reductions of $4 million delivered through efficiency • 43% growth in dem
Slide 7: Improve margins through pricing and efficiency
Improve margins through pricing and efficiency Earnings improvements of $8 million in FY25 • Sustainable margin growth that fully reflects the value proposition of Penthrox® in all markets over time Growth strategy • Fixed cost leverage realised over time • Implement pricing strategies that enable p
Slide 8: Accelerate penetration of Penthrox in Australia
Accelerate penetration of Penthrox in Australia ® Medical led engagement approach to promote faster product adoption over time and support growth in global markets Growth strategy FY25 achievements • Increase medical engagement 9 Encouraging growth in hospital segment, with demand up 43% • Maintain
Slide 9: Grow Penthrox in global markets
Grow Penthrox in global markets ® Leveraging a capital-light partner supported go-to-market strategy in a targeted manner Growth strategy FY25 achievements • Strong partner engagement and knowledge exchange, including 9 European in-market demand up 15% versus the pcp support with external medical/cl
Slide 10: Priorities for FY26
Priorities for FY26 Accelerating volume growth is now the key priority FY26 initiatives Accelerate penetration 1. Local and international knowledge exchange of Penthrox® • Strong partner engagement • Support launch of paediatric label in priority European markets (following national approvals) • Pub
Slide 11: Results
i —_I =) 7) Lu Oo
Slide 12: Results summary
Results summary FY25 Full year results $million FY24 FY25 Change $m Commentary Revenue 33.2 39.1 5.9 • Group revenue up 18% Underlying EBIT (11.6) 0.0 11.6 Underlying Adjustments (before tax)1 (21.5) - 21.5 • Pain Management revenue up 23% driven by growth in underlying demand and higher pricing Rep
Slide 13: Pain Management segment revenue
Pain Management segment revenue Revenue up 23%, higher volumes in Europe and Australia and sustainably improved pricing $million FY24 FY25 Change % Commentary Europe 6.1 8.1 31% Europe Australia 12.3 15.4 26% • Revenue up 31%, with growth in underlying demand of Rest of World 2.7 2.5 (6%) 15% and im
Slide 14: Respiratory segment revenue
Respiratory segment revenue Revenue up 9%, continued share growth in US and improved demand in Australia $million FY24 FY25 Change % Commentary Australia 3.1 3.4 11% Australia USA 6.3 7.3 16% • Stronger demand conditions Europe 1.3 1.2 (2%) • Market share maintained Rest of World 1.2 0.9 (23%) Respi
Slide 15: EBIT bridge
EBIT bridge Pricing and efficiency drive step-change in earnings Underlying EBIT Commentary ($million) Pricing and efficiency FY24 Volume Foreign exchange Other FY25 Underlying EBIT Pricing Efficiency Growth movements Changes Underlying EBIT • Higher pricing in Pain Management, particularly in Austr
Slide 16: Cashflow
Cashflow Free cashflow improved $12.9 million, operating cashflow breakeven for the year Commentary $million FY24 FY25 Change Working capital • Strongly improved operating earnings Operating cash flow (10.8) (0.0) 10.7 • Disciplined working capital management Capital expenditure Capital expenditure
Slide 17: Closing remarks and outlook
Closing remarks and outlook • Margin improvements of $4m FY25 Step-change • Cost reduction of $4m driven by efficiencies • EBIT and cashflow strongly improved in financials • Strong balance sheet, with cash of $17.8m • Increase investment in growth initiatives to embed Penthrox as a standard of care
Slide 18: Appendices
APPENDICES 18
Slide 19: Business overview
Business overview The Pain Management segment delivers more than 67% of Group revenue, driven by demand for Penthrox® in Australia and global markets Pain Management Respiratory Supplies pharmacies, medical clinics and hospitals with a range of Description Manufactures Penthrox® , an inhaled, needle
Slide 20: Penthrox overview
Penthrox overview ® Efficacy, safety and administration benefits of Penthrox® deliver positive patient outcomes and lower overall customer costs1-5 • Inhaled needle-free analgesic 1 The iconic Green Whistle • Non-opioid1 • Portable, self administered device1 • Effective pain relief within 6–10 breat
Slide 21: Reconciliation between underlying EBITDA and net loss after tax
Reconciliation between underlying EBITDA and net loss after tax $million FY24 FY25 Notes FY24 Underlying EBITDA (8.2) 3.2 1. An acceleration of share-based payment expense of $5.1m relating to the cancellation of all share options held by the CEO upon joining the Group LTI program as part of new CEO
Medical Developments International — FY2025 Earnings Presentation on 6ix